* Denies permanent injunction sought by rival Edwards
* Upholds infringement ruling, but no additional damages
* Medtronic: does not impact pivotal CoreValve trial
NEW YORK, Feb 8 A U.S. court refused a request
for a permanent injunction that would have prohibited Medtronic
Inc (MDT.N) from manufacturing its experimental CoreValve
transcatheter heart valve in the United States, the company
Rival Edwards Lifesciences Corp (EW.N) had sought the ban
after a federal jury in April found that Medtronic's CoreValve
infringed an Edwards patent.
Edwards, which was awarded $74 million in that case, was
also seeking further damages. That too was denied in Tuesday's
ruling by the U.S. District Court of Delaware.
The court did uphold the jury's verdict against Medtronic
and the original damages award. Medtronic said it planned to
appeal that decision.
Meanwhile, Medtronic said it does not anticipate any
interruption to supply of its CoreValve System, and that the
court ruling has no impact on its pivotal U.S. clinical trial
of the system, which began in December.
Transcatheter heart valves are inserted through a vein and
seen as a good option for patients deemed too sick for more
invasive open heart procedures to place a replacement valve.
Replacement heart valves are one of the fastest-growing
areas of medical technology.
Medtronic has said it hopes to complete enrollment in its
pivotal CoreValve study in 2012 and launch the product in the
United States in 2014.
(Reporting by Bill Berkrot; Editing by Tim Dobbyn)